"Atazanavir Sulfate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An azapeptide and HIV-PROTEASE INHIBITOR that is used in the treatment of HIV INFECTIONS and AIDS in combination with other ANTI-HIV AGENTS.
Descriptor ID |
D000069446
|
MeSH Number(s) |
D03.383.725.068 D12.644.456.157
|
Concept/Terms |
Atazanavir- Atazanavir
- 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester
BMS 232632- BMS 232632
- 232632, BMS
- BMS-232632
- BMS232632
|
Below are MeSH descriptors whose meaning is more general than "Atazanavir Sulfate".
Below are MeSH descriptors whose meaning is more specific than "Atazanavir Sulfate".
This graph shows the total number of publications written about "Atazanavir Sulfate" by people in this website by year, and whether "Atazanavir Sulfate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Atazanavir Sulfate" by people in Profiles.
-
Himes SK, Huo Y, Siberry GK, Williams PL, Rice ML, Sirois PA, Frederick T, Hazra R, Huestis MA. Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):178-86.
-
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008 Feb; 52(2):631-7.